Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2014 | 1 |
2016 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity.
Nat Commun. 2022 Jul 27;13(1):4319. doi: 10.1038/s41467-022-31757-8.
Nat Commun. 2022.
PMID: 35896531
Free PMC article.
A luminescence-based protocol for assessing fructose metabolism via quantification of ketohexokinase enzymatic activity in mouse or human hepatocytes.
Park SH, Helsley RN, Noetzli L, Tu HC, Wallenius K, O'Mahony G, Boucher J, Liu J, Softic S.
Park SH, et al.
STAR Protoc. 2021 Aug 9;2(3):100731. doi: 10.1016/j.xpro.2021.100731. eCollection 2021 Sep 17.
STAR Protoc. 2021.
PMID: 34409309
Free PMC article.
Item in Clipboard
Management of congenital quantitative fibrinogen disorders: a Delphi consensus.
Casini A, de Moerloose P; Congenital Fibrinogen Disorders Group.
Casini A, et al.
Haemophilia. 2016 Nov;22(6):898-905. doi: 10.1111/hae.13061. Epub 2016 Sep 19.
Haemophilia. 2016.
PMID: 27640400
RESULTS: The main final statements are as follows: (i) a secondary fibrinogen prophylaxis should be started after a first life-threatening bleeding in patients with afibrinogenaemia; (ii) during prophylaxis the target trough fibrinogen level should be 0.5 g L(-1) ; (iii) i …
RESULTS: The main final statements are as follows: (i) a secondary fibrinogen prophylaxis should be started after a first life-threatening b …
Item in Clipboard
Population pharmacokinetic study of memantine: effects of clinical and genetic factors.
Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Alnawaqil AM, Maurer S, Zumbach S, Giannakopoulos P, von Gunten A, Csajka C, Eap CB.
Noetzli M, et al.
Clin Pharmacokinet. 2013 Mar;52(3):211-23. doi: 10.1007/s40262-013-0032-2.
Clin Pharmacokinet. 2013.
PMID: 23371894
Patients were genotyped for common polymorphisms in renal cation transporters (SLC22A1/2/5, SLC47A1, ABCB1) and nuclear receptors (NR1I2, NR1I3, RXR, PPAR) involved in transporter expression. RESULTS: The average clearance was 5.2 L/h with a 27 % inter-individual variabili …
Patients were genotyped for common polymorphisms in renal cation transporters (SLC22A1/2/5, SLC47A1, ABCB1) and nuclear receptors (NR1I2, NR …
Item in Clipboard
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.
Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Stancu I, Alnawaqil AM, Bula C, Zumbach S, Gaillard M, Giannakopoulos P, von Gunten A, Csajka C, Eap CB.
Noetzli M, et al.
Br J Clin Pharmacol. 2014 Jul;78(1):135-44. doi: 10.1111/bcp.12325.
Br J Clin Pharmacol. 2014.
PMID: 24433464
Free PMC article.
Clinical Trial.
The patients were genotyped for common polymorphisms in the metabolic enzymes CYP2D6 and CYP3A, in the electron transferring protein POR and the nuclear factor NR1I2 involved in CYP activity and expression, and in the drug transporter ABCB1. RESULTS: The average donepezil clearan …
The patients were genotyped for common polymorphisms in the metabolic enzymes CYP2D6 and CYP3A, in the electron transferring protein POR and …
Item in Clipboard
Cite
Cite